Form 4: Natera CEO Steven Chapman Sells Shares Under 10b5-1 Trading Plan

Natera's CEO, Steven Leonard Chapman, sold shares of the company's common stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 16, 2024, Steven Leonard Chapman, the CEO and President of Natera, Inc., sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2023.
• A total of 5,024 shares were sold in multiple transactions at varying prices.
• The prices ranged from $126.35 to $131.18 per share.
• Following the reported transactions, Chapman still beneficially owns 195,686 shares of Natera's common stock.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting stock sales. The sentiment is neutral as the sales were pre-planned.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although sales under a 10b5-1 plan are typically viewed as less concerning since they are pre-planned.

Industry Context

Insider trading activity is always closely watched in the biotech industry, especially for companies like Natera that are in a high-growth and competitive market. Sales under 10b5-1 plans are common and provide a legal framework for insiders to diversify their holdings.

Comparison to Industry Standards

• Executive compensation and stock ownership are common metrics for comparison across the biotech industry.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) are competitors in the liquid biopsy space, and their executive compensation and stock ownership structures are often compared to Natera's.
• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates potential concerns.

Key Dates